↓ Skip to main content

Chlorpromazine versus placebo for schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

blogs
2 blogs
twitter
23 tweeters
peer_reviews
1 peer review site
weibo
1 weibo user
facebook
1 Facebook page
video
1 video uploader

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
284 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Chlorpromazine versus placebo for schizophrenia
Published in
Cochrane database of systematic reviews, January 2014
DOI 10.1002/14651858.cd000284.pub3
Pubmed ID
Authors

Clive E Adams, George A Awad, John Rathbone, Ben Thornley, Karla Soares-Weiser

Abstract

Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia.

Twitter Demographics

The data shown below were collected from the profiles of 23 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 284 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Netherlands 1 <1%
Canada 1 <1%
Unknown 281 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 55 19%
Researcher 41 14%
Student > Bachelor 37 13%
Student > Ph. D. Student 37 13%
Student > Doctoral Student 23 8%
Other 54 19%
Unknown 37 13%
Readers by discipline Count As %
Medicine and Dentistry 88 31%
Psychology 56 20%
Nursing and Health Professions 28 10%
Social Sciences 19 7%
Pharmacology, Toxicology and Pharmaceutical Science 15 5%
Other 35 12%
Unknown 43 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2017.
All research outputs
#894,372
of 16,725,085 outputs
Outputs from Cochrane database of systematic reviews
#2,406
of 11,580 outputs
Outputs of similar age
#14,310
of 269,596 outputs
Outputs of similar age from Cochrane database of systematic reviews
#33
of 159 outputs
Altmetric has tracked 16,725,085 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,580 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.4. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,596 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 159 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.